Clinical Application of Dual Sentinel Lymph Node Staining Method in Breast Cancer Patients

• Status: Unknown status
• Trial end date: 2017-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study aimed to compare detection rate between dual sentinel node staining method using mixture of indocyanine green (ICG) with radioisotope(RI), and RI only.

To identify the first lymph node(s) along the lymphatic drainage pathway from the primary tumor in the breast cancer using RI only has several disadvantages such as invisibility, interference. As ICG can be visualized with a fluorescence imaging system, we expects dual sentinel lymph node staining method had better outcomes.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Center, Korea

Criteria

Inclusion Criteria:

• breast cancer patients who receive neoadjuvant therapy (chemotherapy,hormonal therapy, targeted therapy)

• cN1-cN2 or cN3( but must be complete response status)on tumor lymphnode metastasis classification( TNM) after neoadjuvant therapy.

• ECOG Performance status 0 or 1

• consented patients with more than 20 years, less than 70 years

Exclusion Criteria:

• history of breast cancer

• early stage breast cancer

• history of excisional or incisional biopsy or axillary dissection

• inflammatory breast carcinoma

• cN3 on tumor lymphnode metastasis classification(TNM)

• stage 4 breast cancer

• pregnancy